Pharmaceutisch Weekblad

, Volume 10, Issue 2, pp 69–75 | Cite as

Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer

  • C. H. W. Koks
  • J. R. B. J. Brouwers
  • D. Th. Sleijfer
Update Articles


Recent reports on regional chemotherapy for hepatic metastases of colorectal origin are reviewed. Because of reported side effects and lack of evidence for its superiority over conventional intravenous administration, intra-arterial administration of fluoropyrimidines cannot be advised for routine use, but should be restricted to centres participating in clinical trials on this subject.


5-Fluorouracil Floxuridine Infusions, intra-arterial Liver Neoplasm metastasis Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Van de Velde CJH. Die chirurgische Therapie der Lebermetastasen. In: Aigner KR, ed. Beiträge zur Onkologie. Band 21. Basle: Karger, 1985:6–21.Google Scholar
  2. 2.
    Kemeny N. The systemic chemotherapy of hepatic metastases. Semin Oncol 1983;10:148–58.Google Scholar
  3. 3.
    Speyer JL. Intraperitoneal chemotherapy. A possible role in the treatment of hepatic metastases. In: Van de Velde CJH, Sugarbaker PH, eds. Liver metastasis. Dordrecht: Martinus Nijhoff Publishers, 1984:249–62.Google Scholar
  4. 4.
    Rosenberg SA, Lotze MT, Uul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987;316:889–97.Google Scholar
  5. 5.
    Ackermann NB, Lien WM, Kondi ES, Silverman NA. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to ‘small’ and ‘large tumours’. Surgery 1969;66:1067–72.Google Scholar
  6. 6.
    Collins JM, Dedrick RL. Pharmacokinetics of anti-cancer drugs. In: Chabner B, ed. Pharmacologic principles of cancer treatment. Philadelphia: WB Saunders, 1982:77–99.Google Scholar
  7. 7.
    Ensminger W, Stetson P, Gyves J, et al. Dependence of hepatic arterial fluorouracil pharmacokinetics on dose rate and duration of infusion. Proc Am Soc Clin Oncol 1983;2:25(C-98).Google Scholar
  8. 8.
    Ensminger WD, Rosowsky A, Raso V, et al. A clinical pharmacologic evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784–92.Google Scholar
  9. 9.
    Sigurdson ER, Ridge JA, Daly JM. Fluorodeoxyuridine uptake by human colorectal hepatic metastases after hepatic artery infusion. Surgery 1986;100:285–91.Google Scholar
  10. 10.
    Wagner JG, Gyves JW, Stetson PL, et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusion in cancer patients. Cancer Res 1986;46:1499–506.Google Scholar
  11. 11.
    Petit E, Milano G, Levi F, Thyss A, Schneider M, Bailleul F. Chronopharmacocinetique du 5 FU en administration continue. Proceedings of drug delivery systems; neurological and oncologic applications. Sophia: Antipolis, 1987:93.Google Scholar
  12. 12.
    Ridge JA, Daly JM. Treatment of colorectal hepatic metastases. Surg Gynecol Obstet 1985;161:597–607.Google Scholar
  13. 13.
    Jaffe BM, Donegan WL, Watson F, Spratt JS. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968; 127:1–11.Google Scholar
  14. 14.
    Wood CB, Gillis CR, Blumgart LH. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 1976; 2:285–8.Google Scholar
  15. 15.
    Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DC. Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Ann Intern Med 1984;100:736–43.Google Scholar
  16. 16.
    Thirlwell MP, Hollingsworth LM, Herba MJ, Boileau G, Boos G, Macfarlane JK. Ambulatory hepatic artery infusion chemotherapy for cancer of the liver. Am J Surg 1986;151:585–9.Google Scholar
  17. 17.
    Grage TB, Vassilopoulos PP, Shingleton WW, et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a central oncology group study. Surgery 1979;86:550–5.Google Scholar
  18. 18.
    Kemeny N, Daly J, Reichman J, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastasis from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107:459–65.Google Scholar
  19. 19.
    Hohn D, Stagg R, Friedman M, et al. The NCOG randomized trial of intravenous versus hepatic arterial FUdR for colorectal cancer metastatic to the liver. Proceedings. Washington: American Society of Clinical Oncology, 1987:85(333).Google Scholar
  20. 20.
    Balch CM, Urist MM, Soon SJ, McGregor M. A prospective phase II clinical trial of continuous FUdR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 1983;198:567–73.Google Scholar
  21. 21.
    Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984;53:1336–43.Google Scholar
  22. 22.
    Schwartz SI, Jones LS, McCune CS. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 1985;201:560–7.Google Scholar
  23. 23.
    Cohen AM, Kaufman SD, Wood WC. Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy. Dis Colon Rectum 1985;28:389–93.Google Scholar
  24. 24.
    Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985;3:161–9.Google Scholar
  25. 25.
    Johnson LP, Rivkin SE. The implanted pump in metastatic colorectal cancer of the liver. Risk versus benefit. Am J Surg 1985;149:595–8.Google Scholar
  26. 26.
    Ramming KP, O'Toole K. The use of the implanted chemoinfusion pump in the treatment of hepatic metastases of colorectal cancer. Arch Surg 1986;121:1440–4.Google Scholar
  27. 27.
    Fortner JG, Silva JS, Cox EB, Golbey RB, Gallowitz H, Maclean B. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg 1984;199:317–24.Google Scholar
  28. 28.
    Ackermann NB. Experimental studies on the role of the portal circulation in hepatic tumour vascularity. Cancer 1986;58:1653–7.Google Scholar
  29. 29.
    Kemeny MM, Battiflora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUdR. Am Surg 1985;202:176–181.Google Scholar
  30. 30.
    Hohn DC, Rayner AA, Economou JS, Ignoffo RJ, Lewis BJ, Stagg RJ. Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 1986;57:465–70.Google Scholar
  31. 31.
    Hohn DC, Stagg RJ, Price DC, Lewis BJ. Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. J Clin Oncol 1985;3:1257–60.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1988

Authors and Affiliations

  • C. H. W. Koks
    • 1
  • J. R. B. J. Brouwers
    • 1
  • D. Th. Sleijfer
    • 2
  1. 1.Department of Clinical PharmacyGeneral Hospital De TjongerschansMA Heerenveenthe Netherlands
  2. 2.Department of Internal Medicine and OncologyUniversity Hospital GroningenRB Groningenthe Netherlands

Personalised recommendations